JP2005527547A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005527547A5 JP2005527547A5 JP2003579739A JP2003579739A JP2005527547A5 JP 2005527547 A5 JP2005527547 A5 JP 2005527547A5 JP 2003579739 A JP2003579739 A JP 2003579739A JP 2003579739 A JP2003579739 A JP 2003579739A JP 2005527547 A5 JP2005527547 A5 JP 2005527547A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- trefoil peptide
- agent
- chemotherapeutic agent
- trefoil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 15
- 108010007389 Trefoil Factors Proteins 0.000 claims 13
- 102000007641 Trefoil Factors Human genes 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 13
- 239000002246 antineoplastic agent Substances 0.000 claims 10
- 229940127089 cytotoxic agent Drugs 0.000 claims 10
- 102100039145 Trefoil factor 3 Human genes 0.000 claims 6
- 230000002411 adverse Effects 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 102000008817 Trefoil Factor-1 Human genes 0.000 claims 2
- 108010088412 Trefoil Factor-1 Proteins 0.000 claims 2
- 102000014456 Trefoil Factor-3 Human genes 0.000 claims 2
- 108010078184 Trefoil Factor-3 Proteins 0.000 claims 2
- 230000002921 anti-spasmodic effect Effects 0.000 claims 2
- 230000004071 biological effect Effects 0.000 claims 2
- 239000000812 cholinergic antagonist Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 229960003685 imatinib mesylate Drugs 0.000 claims 2
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 208000004232 Enteritis Diseases 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 206010028116 Mucosal inflammation Diseases 0.000 claims 1
- 201000010927 Mucositis Diseases 0.000 claims 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 229960002092 busulfan Drugs 0.000 claims 1
- 229960004117 capecitabine Drugs 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 1
- 229960001924 melphalan Drugs 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 231100000017 mucous membrane irritation Toxicity 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000001297 phlebitis Diseases 0.000 claims 1
- 229960004964 temozolomide Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36757402P | 2002-03-26 | 2002-03-26 | |
| US42270802P | 2002-10-31 | 2002-10-31 | |
| PCT/US2003/009195 WO2003082196A2 (en) | 2002-03-26 | 2003-03-26 | Combination therapy using trefoil peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005527547A JP2005527547A (ja) | 2005-09-15 |
| JP2005527547A5 true JP2005527547A5 (https=) | 2006-03-23 |
Family
ID=28678188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003579739A Pending JP2005527547A (ja) | 2002-03-26 | 2003-03-26 | トレフォイル・ペプチドを使用した組み合わせ療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20030186880A1 (https=) |
| EP (1) | EP1494530A4 (https=) |
| JP (1) | JP2005527547A (https=) |
| CN (1) | CN1655675A (https=) |
| AU (1) | AU2003224773B2 (https=) |
| CA (1) | CA2480372A1 (https=) |
| MX (1) | MXPA04009363A (https=) |
| WO (1) | WO2003082196A2 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6525018B1 (en) | 1999-05-17 | 2003-02-25 | The General Hospital Corp. | Treating eye disorders using intestinal trefoil proteins |
| US20030185838A1 (en) * | 2001-11-28 | 2003-10-02 | Podolsky Daniel K. | Methods and compositions for treating lesions of the respiratory epithelium |
| US20030186882A1 (en) * | 2001-07-31 | 2003-10-02 | Podolsky Daniel K. | Methods and compositions for treating and preventing distal bowel lesions |
| US20040171544A1 (en) * | 2001-04-24 | 2004-09-02 | Barker Nicholas P. | Trefoil domain-containing polypeptides and uses thereof |
| US20060189526A1 (en) * | 2002-04-24 | 2006-08-24 | Podolsky Daniel K | Compositions containing an intestinal trefoil peptide and a mucoadhesive |
| US7538082B2 (en) | 2001-04-24 | 2009-05-26 | The General Hospital Corporation | Methods and compositions for treating oral and esophageal lesions |
| US20030105016A1 (en) * | 2001-09-06 | 2003-06-05 | Podolsky Daniel K. | Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions |
| US20030181384A1 (en) * | 2001-09-06 | 2003-09-25 | Podolsky Daniel K. | Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions |
| WO2003030824A2 (en) * | 2001-10-05 | 2003-04-17 | The General Hospital Corporation | Methods and compositions for treating dermal lesions |
| US20030185839A1 (en) * | 2001-10-05 | 2003-10-02 | Podolsky Daniel K. | Methods and compositions for treating dermal lesions |
| JP2006516964A (ja) * | 2002-10-31 | 2006-07-13 | ザ ジーアイ カンパニー インコーポレーティッド | 三つ葉型ドメイン含有ポリペプチドおよびその使用 |
| US20060188471A1 (en) * | 2002-10-31 | 2006-08-24 | Podolsky Daniel K | Methods of treating epithelial lesions |
| US8075771B2 (en) * | 2005-02-17 | 2011-12-13 | E. I. Du Pont De Nemours And Company | Apparatus for magnetic field gradient enhanced centrifugation |
| CN100381560C (zh) * | 2005-09-27 | 2008-04-16 | 中国人民解放军第三军医大学第一附属医院 | 采用gs115酵母菌合成重组人肠三叶因子的工艺 |
| WO2013176785A1 (en) * | 2012-05-21 | 2013-11-28 | The Trustees Of Columbia University In The City Of New York | Trefoil family factor and uses thereof |
| US11559580B1 (en) | 2013-09-17 | 2023-01-24 | Blaze Bioscience, Inc. | Tissue-homing peptide conjugates and methods of use thereof |
| WO2017044894A2 (en) | 2015-09-09 | 2017-03-16 | Fred Hutchinson Cancer Research Center | Cartilage-homing peptides |
| CA3033004A1 (en) | 2016-09-09 | 2018-03-15 | Fred Hutchinson Cancer Research Center | Stable peptides and methods of use thereof |
| WO2018136614A1 (en) | 2017-01-18 | 2018-07-26 | Fred Hutchinson Cancer Research Center | Peptide compositions and methods of use thereof for disrupting tead interactions |
| EP3595699A4 (en) | 2017-03-16 | 2020-12-23 | Blaze Bioscience, Inc. | PEPTIDIC CONJUGATES OF CARTILAGE ECOTROPISM AND THEIR METHODS OF USE |
| EP3638290A4 (en) | 2017-06-15 | 2021-04-07 | Blaze Bioscience, Inc. | KIDNEY HOMING PEPTIDE CONJUGATES AND METHOD OF USING THEREOF |
| CA3086040A1 (en) | 2017-12-19 | 2019-06-27 | Blaze Bioscience, Inc. | Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof |
| JP7579880B2 (ja) * | 2020-03-30 | 2024-11-08 | 山東睿鷹制薬集團有限公司 | 新型コロナウイルス感染の治療におけるＴＦＦ２タンパク質とＩＦＮ－κタンパク質の併用の応用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US151472A (en) * | 1874-06-02 | Improvement in rotary engines | ||
| US4370317A (en) * | 1980-09-10 | 1983-01-25 | Novo Industri A/S | Pancreatic spasmolytic polypeptide |
| US5843701A (en) * | 1990-08-02 | 1998-12-01 | Nexstar Pharmaceticals, Inc. | Systematic polypeptide evolution by reverse translation |
| US6221840B1 (en) * | 1991-02-14 | 2001-04-24 | The General Hospital Corporation | Intestinal trefoil proteins |
| US6063755A (en) * | 1991-02-14 | 2000-05-16 | The General Hospital Corporation | Intestinal trefoil proteins |
| US5703047A (en) * | 1992-09-21 | 1997-12-30 | Board Of Regents, The University Of Texas System | Methods and treatments for corneal healing with growth factors |
| DK6893D0 (da) * | 1993-01-21 | 1993-01-21 | Novo Nordisk As | Peptid |
| US5563046A (en) * | 1993-08-02 | 1996-10-08 | Celtrix Pharmaceuticals, Inc. | Fusion polypeptides and proteins |
| US5478858A (en) * | 1993-12-17 | 1995-12-26 | The Procter & Gamble Company | 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists |
| CA2196876C (en) * | 1994-08-26 | 2007-04-17 | Lars Thim | Trefoil peptide dimer |
| US6525018B1 (en) * | 1999-05-17 | 2003-02-25 | The General Hospital Corp. | Treating eye disorders using intestinal trefoil proteins |
| US20030185838A1 (en) * | 2001-11-28 | 2003-10-02 | Podolsky Daniel K. | Methods and compositions for treating lesions of the respiratory epithelium |
| US20030186882A1 (en) * | 2001-07-31 | 2003-10-02 | Podolsky Daniel K. | Methods and compositions for treating and preventing distal bowel lesions |
| US20030114384A1 (en) * | 2001-11-28 | 2003-06-19 | Podolsky Daniel K. | Methods and compositions for treating lesions of the respiratory epithelium |
| WO1999010377A1 (en) * | 1997-08-25 | 1999-03-04 | The General Hospital Corporation | Receptor for intestinal trefoil factor |
| BR9913152A (pt) * | 1998-08-26 | 2001-05-15 | Smithkline Beecham Corp | Terapias para tratamento de doenças pulmonares |
| US6372439B2 (en) * | 1998-10-01 | 2002-04-16 | James R. Goldenring | Screen for gastric adenocarcinoma |
| PT1739178E (pt) * | 1999-07-05 | 2010-11-17 | Actogenix Nv | Libertação de péptidos trifólios |
| AU2020501A (en) * | 1999-12-08 | 2001-06-18 | 1149336 Ontario Inc. | Chemotherapy treatment |
| CA2391594A1 (en) * | 1999-12-23 | 2001-06-28 | Human Genome Sciences, Inc. | Trefoil domain-containing polynucleotides, polypeptides, and antibodies |
| EP1609468A3 (en) * | 2000-11-22 | 2006-01-25 | Rxkinetix, Inc. | A composition on the basis of a sulfur-containing antioxidant and its use for the manufacture of a medicament for treating mucositis |
| MXPA03009772A (es) * | 2001-04-24 | 2004-02-23 | Gen Hospital Corp | Metodos y composiciones para tratar lesiones orales y del esofago. |
| US20030105016A1 (en) * | 2001-09-06 | 2003-06-05 | Podolsky Daniel K. | Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions |
| US7538082B2 (en) * | 2001-04-24 | 2009-05-26 | The General Hospital Corporation | Methods and compositions for treating oral and esophageal lesions |
| US20030153496A1 (en) * | 2001-06-14 | 2003-08-14 | Lars Thim | Mucosal repair by TFF dimer peptides |
| EP1418930A2 (en) * | 2001-06-14 | 2004-05-19 | Novo Nordisk A/S | Mucosal repair by tff2 peptides |
| AU2002318935A1 (en) * | 2001-07-31 | 2003-02-17 | The General Hospital Corporation | Methods and compositions for treating and preventing distal bowel lesions |
| US20030181384A1 (en) * | 2001-09-06 | 2003-09-25 | Podolsky Daniel K. | Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions |
| WO2003030824A2 (en) * | 2001-10-05 | 2003-04-17 | The General Hospital Corporation | Methods and compositions for treating dermal lesions |
| US20030185839A1 (en) * | 2001-10-05 | 2003-10-02 | Podolsky Daniel K. | Methods and compositions for treating dermal lesions |
| US20030215431A1 (en) * | 2002-02-11 | 2003-11-20 | Lars Thim | Management of mucosal viscosity by TFF monomer peptides |
| US6780383B1 (en) * | 2003-02-28 | 2004-08-24 | Eugene Ettlinger | System for sterilization of spaces and surfaces |
| US6984628B2 (en) * | 2003-07-15 | 2006-01-10 | Allergan, Inc. | Ophthalmic compositions comprising trefoil factor family peptides |
| EP1893953A2 (en) * | 2005-05-18 | 2008-03-05 | The GI Company, Inc | Oral drug delivery system and methods of use thereof |
| WO2007014197A2 (en) * | 2005-07-25 | 2007-02-01 | The G.I. Company, Inc. | Yeast expression vectors for production of itf |
-
2003
- 2003-03-26 AU AU2003224773A patent/AU2003224773B2/en not_active Ceased
- 2003-03-26 CA CA002480372A patent/CA2480372A1/en not_active Abandoned
- 2003-03-26 JP JP2003579739A patent/JP2005527547A/ja active Pending
- 2003-03-26 MX MXPA04009363A patent/MXPA04009363A/es unknown
- 2003-03-26 EP EP03721462A patent/EP1494530A4/en not_active Withdrawn
- 2003-03-26 US US10/397,953 patent/US20030186880A1/en not_active Abandoned
- 2003-03-26 WO PCT/US2003/009195 patent/WO2003082196A2/en not_active Ceased
- 2003-03-26 CN CNA038120402A patent/CN1655675A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005527547A5 (https=) | ||
| US6509154B1 (en) | Product comprising at least a double stranded RNA combined with at least an antiviral agent | |
| CN102159245B (zh) | Hcv ns3蛋白酶抑制剂与干扰素和利巴韦林的组合 | |
| ES2333399T3 (es) | Metodos para tratar una leucemia. | |
| JP2009504157A5 (https=) | ||
| AU2003224773B2 (en) | Combination therapy using trefoil peptides | |
| CA2359812A1 (en) | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures | |
| JP2818299B2 (ja) | ウイルス感染の治療におけるジデオキシヌクレオシドアナローグの使用 | |
| RU2011139180A (ru) | Комбинация нуклеозидного ингибитора полимеразы и макроциклического ингибитора протеазы и ее применение для лечения гепатита с, фиброза печени и нарушенной печеночной функции | |
| JP2015057436A5 (https=) | ||
| DK1453487T3 (da) | Farmaceutisk doseringsform med flere belægninger for reduceret virkning af belægningsbrud | |
| WO1997006804A1 (en) | 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis c | |
| JP2006514092A5 (https=) | ||
| CN102596201A (zh) | 包含BI201335、干扰素α和利巴韦林的HCV组合治疗的用药方案 | |
| JP2005525784A5 (https=) | ||
| JP2008526953A (ja) | 炎症性疾患のプラジカンテルでの治療 | |
| JP2002326936A5 (https=) | ||
| KR20090130063A (ko) | 척수 외상의 치료를 위한 4-시클로프로필메톡시-ｎ-(3,5-디클로로-1-옥시도피리딘-4-일)-5-(메톡시)피리딘-2-카르복스아미드의 용도 | |
| RU2417083C2 (ru) | Применение активаторов растворимой гуанилатциклазы для лечения острых и хронических легочных заболеваний | |
| JP2007504223A5 (https=) | ||
| CA2141951C (en) | Inhibition of retrovirus infection | |
| TW200911247A (en) | Use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for preparing a medicament for use in the treatment of motor disorders related to parkinson's disease | |
| JP2012504941A5 (https=) | ||
| JP2007504222A5 (https=) | ||
| WO2002056916A8 (en) | Compositions and methods for enhanced pharmacological activity through oral and parenteral administration of compositions comprising polypeptide drug substances and other poorly absorbed active ingredients |